Cited by 148Glaucoma and retinal disordersNeuroinflammation and Neurodegeneration MechanismsRetinal Diseases and Treatments

GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension

Open access
Sterling, Jacob K., Adetunji, Modupe O., Guttha, Samyuktha, Bargoud, Albert R., Uyhazi, Katherine E., Ross, Ahmara G., Dunaief, Joshua L., Cui, Qi N.·2020·Cell Reports

Published version of a preprint

Abstract

Glaucoma is the leading cause of irreversible blindness and is characterized by the death of retinal ganglion cells (RGCs). Recent studies have implicated pro-inflammatory microglia, macrophages, and A1 astrocytes in the pathogenesis of neurodegenerative diseases. The role of pro-inflammatory, neurotoxic A1 astrocytes in glaucoma is just beginning to be explored. Using a mouse model of glaucoma, we demonstrate that ocular hypertension is sufficient to trigger production of C1q, interleukin-1α (IL-1α), and tumor necrosis factor α (TNF-α), three cytokines necessary and sufficient to drive the formation of A1 astrocytes. Upregulation of these cytokines occurs first in CD11b + CD11c + cells followed by CD11b + CD11c − cells. Ablation of this pathway, by either genetic deletions of C1qa, IL-1α, and TNF-α, or treatment with glucagon-like peptide-1 receptor agonist NLY01, reduces A1 astrocyte transformation and RGC death. Together, these results highlight a neuroinflammatory mechanism of glaucomatous neurodegeneration that can be therapeutically targeted by NLY01 administration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2020.108271

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elovl1 cKO mice still showed neuronal death following ONC, unlike Il1a−/−Tnf−/−C1qa−/− mice, which show no RGC death following axon crush, but the amount of death was reduced.

    “While Elovl1 cKO mice still showed neuronal death following ONC (unlike in Il1a−/−Tnf−/−C1qa−/− mice, which show no RGC death following axon crush2,3,20), the amount of death was reduced”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 52 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Sterling, J. K., Adetunji, M. O., Guttha, S., Bargoud, A. R., Uyhazi, K. E., Ross, A. G., Dunaief, J. L., & Cui, Q. N.
Affiliations
  • University of Pennsylvania (US)
  • University of Pennsylvania Health System (US)
Corresponding author
  • Sterling, Jacob K.
  • Cui, Qi N.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2020-11
Volume
33
Issue
5
Pages
108271
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3096251629
Cited by
148
References
52
Citations by year
2026: 30 · 2025: 31 · 2024: 21 · 2023: 24 · 2022: 20 · 2021: 22
FWCI
13.10
Type
journal article
Language
en
Open access
Locations
  • Cell Reports (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (R01EY015240, R01EY028916)
  • Research to Prevent Blindness
  • American Glaucoma Society (T32EY007035, T32GM007170)
  • Paul MacKall and Evanina Bell MacKall Trust
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
glaucoma, GLP-1 receptor agonists, ocular hypertension, retinal ganglion cell death, neuroinflammation, C1q, interleukin-1 alpha, TNF-α, microglia, macrophages, glaucomatous neurodegeneration
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Astrocytes, Female, Inflammation, Intraocular Pressure, Male, Mice, Inbred C57BL, Ocular Hypertension, Retinal Ganglion Cells, Tumor Necrosis Factor-alpha, Complement C1q, Cell Death, CD11b Antigen, Interleukin-1alpha, Retinal Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review